Ionis Pharmaceuticals
IONS
314 hedge funds and large institutions have $4.23B invested in Ionis Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 122 increasing their positions, 85 reducing their positions, and 58 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 122 | Existing positions reduced: 85
6% less funds holding
Funds holding: 334 → 314 (-20)
15% less call options, than puts
Call options by funds: $35M | Put options by funds: $41.2M
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
31% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 58
34% less capital invested
Capital invested by funds: $6.4B → $4.23B (-$2.17B)
Top Buyers
| 1 |
ClearBridge Investments
New York
|
+$67M |
| 2 |
Millennium Management
New York
|
+$43.8M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$20.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$16.8M |
| 5 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
+$16.7M |
Top Sellers
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$50.2M |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
-$38.3M |
| 3 |
Goldman Sachs
New York
|
-$29.2M |
| 4 |
Two Sigma Investments
New York
|
-$28.6M |
| 5 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$18.6M |
IONS Hedge Fund Activity: Q1 2016 in Review
314 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q1 2016, worth a combined $4.23B — down 34% from $6.4B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of IONS and 40 opened new positions — a net loss of 18 holders — while 85 trimmed existing stakes and 122 added.
The largest buyer was ClearBridge Investments, adding an estimated $67M. The largest seller was First Trust Advisors, cutting an estimated $50.2M.
- 314 institutional investors held Ionis Pharmaceuticals (IONS) as of Q1 2016, down from 334 in Q4 2015.
- Funds reported $4.23B of Ionis Pharmaceuticals stock for Q1 2016, down 34% quarter-over-quarter.
- 40 funds opened new Ionis Pharmaceuticals positions in Q1 2016 and 58 closed out, a net change of -18 holders.
- The largest Ionis Pharmaceuticals buyer in Q1 2016 was ClearBridge Investments, an estimated $67M added.
- The largest Ionis Pharmaceuticals seller in Q1 2016 was First Trust Advisors, an estimated $50.2M sold.
Based on aggregated 13F filings for Q1 2016.